Eligibility Criteria

Patients must:
1. Be 40 to 79 years age, with a definitive histological diagnosis of PCa by needle biopsy.
2. Have high risk PCa where at least one of the following three factors is satisfied:
   1) initial PSA > 20 ng/mL, 2) Clinical stage of T2c or T3a, 3) Gleason score 8-10.
3. Be previously untreated for prostate cancer.
4. Demonstrate appropriate bone marrow, hepatic and renal function in laboratory tests within two weeks prior to registration.
   a) WBC ≥ 3,000 /µL
   b) Hemoglobin level ≥ 10.0 g/dL
   c) Platelet count ≥ 10.0 × 10⁴/µL
   d) Serum creatine level ≤ 2.0 mg/dL
   e) ALT and AST levels ≤ 100 IU/L
5. Agree in writing to participate in this clinical study after receiving adequate explanation.